Seed
Yopo Bean
Strong EvidenceCompound1 PubMed Study
Hermetica Superfood Encyclopedia
Yopo Bean (Anadenanthera peregrina) contains bufotenin as its primary bioactive compound at concentrations up to 74 mg per gram, alongside trace amounts of 5-MeO-DMT and N,N-DMT. These tryptamine alkaloids act as serotonin receptor agonists, particularly at 5-HT2B receptors with Ki values of 6.2-630 nM, producing psychoactive effects traditionally used in indigenous shamanic practices.
Yopo Bean (Anadenanthera peregrina) is a leguminous tree native to the Amazon and Caribbean regions of Venezuela, Colombia, and Brazil. Its seeds have been historically significant in indigenous cultures for their unique bioactive compounds. This powerful seed is recognized for its potential cognitive-enhancing, adaptogenic, and circulatory-supporting properties.
Research, including in vitro and preliminary animal studies, suggests Yopo Bean's potential for neuroprotective, adaptogenic, and circulatory benefits, primarily attributed to its alkaloid and polyphenol content. Further human clinical trials are necessary to fully elucidate its efficacy and safety for cognitive and mood support.
- Macros: Prebiotic fiber - Vitamins: Tocopherols (Vitamin E) - Minerals: Potassium, magnesium, zinc - Phytochemicals/Bioactives: Alkaloids (tryptamines), polyphenols, flavonoids (quercetin, catechins), plant sterols
Bufotenin, the primary bioactive compound in yopo beans, acts as an agonist at multiple 5-HT receptor subtypes, with highest affinity for 5-HT2B receptors (Ki 6.2-630 nM) and moderate affinity for 5-HT2A receptors (Ki 15->10,000 nM). The compound produces psychoactive effects through serotonergic pathway activation, with enhanced potency when combined with MAO-inhibiting β-carbolines from Banisteriopsis caapi. Additional tryptamine alkaloids including 5-MeO-DMT and N,N-DMT contribute to the overall pharmacological profile through similar serotonin receptor mechanisms.
No modern human clinical trials have been conducted specifically on yopo beans, with available evidence limited to historical bufotenin studies from the 1950s onward that lack detailed quantitative outcomes. Animal studies indicate an intraperitoneal LD50 of 200-300 mg/kg for bufotenin in rodents, which scales to approximately 135 grams of beans for a lethal dose in a 50 kg human. Early insufflation experiments in 25-30g rodents demonstrated rapid onset effects within 3 minutes, progressing to dyspnea at 5-6 minutes and convulsions at 8 minutes, with recovery occurring at 35-40 minutes. Human intravenous bufotenin trials showed significant peripheral toxicity including tachycardia and respiratory difficulty at doses as low as 8 mg, highlighting the narrow therapeutic window and safety concerns.
Yopo beans present significant safety risks due to bufotenin's toxicity profile, with human intravenous studies showing dangerous cardiovascular effects (tachycardia, respiratory arrest, facial discoloration) at 8 mg doses. Animal studies demonstrate intense nasal irritation, agitation, and convulsions with insufflated administration, though this route shows fewer side effects than injection. Synergistic interactions occur with MAO-inhibiting plants like Banisteriopsis caapi, which potentiate and prolong psychoactive effects through enhanced bufotenin activity. Contraindications include cardiovascular or respiratory vulnerabilities, and extreme caution is warranted given the estimated lethal dose of approximately 135 grams of beans for a 50 kg adult based on animal LD50 data.
